Population pharmacokinetic (PK) analysis from phase 1 and 2 studies of the HER3 inhibitor patritumab in patients with advanced non-small cell lung cancer (NSCLC) or solid tumors.

Satoshi Yoshiba,Mendel Jansen,Nobuko Matsushima,Xiaoping Jin,Jeanne Mendell-Harary

Population pharmacokinetic (PK) analysis from phase 1 and 2 studies of the HER3 inhibitor patritumab in patients with advanced non-small cell lung cancer (NSCLC) or solid tumors.

2014

Satoshi Yoshiba
Mendel Jansen
Nobuko Matsushima
Xiaoping Jin
Jeanne Mendell-Harary

2587 Background: Patritumab is a fully human antibody specific to HER3, a HER family receptor implicated in tumor resistance to anticancer treatment. In order to support patritumab dose recommendat...

Keywords:

non-small cell lung cancer (NSCLC)
Pathology
Oncology
Population
Patritumab
Medicine
Internal medicine
Pharmacokinetics
Cancer research
Receptor
tumor resistance
Antibody
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations